Gabapentin
Product Images NDC 50436-0224

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-0224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

Mathematical formula for calculating creatinine clearance (CLCr) based on age, weight, and serum creatinine, with adjustment for female patients by multiplying by 0.85. The formula is presented as text likely within prescribing information or clinical guidelines for Gabapentin by Unit Dose Services.*

FDA Label Image

Gabapentin Fig1

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks divided into a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin scores decrease steadily over time, while placebo scores remain relatively stable.*

FDA Label Image

Gabapentin Fig2

Line chart showing mean pain scores over a 7-week period comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreased pain scores with Gabapentin doses relative to placebo.*

FDA Label Image

Gabapentin Fig3

A bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint from controlled postherpetic neuralgia (PHN) studies for Gabapentin (GBP) versus placebo (PBO). Study 1 shows 12% for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing the percentage difference on the y-axis versus daily dose in milligrams on the x-axis for Gabapentin across three studies labeled a, b, and c. The graph illustrates comparative differences at doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg, with distinct symbols and shading representing each study group.*

FDA Label Image

Gabapentin-struc (Gabapentin Struc)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to an aminomethyl group and an acetic acid moiety.*

FDA Label Image

Label Image (Lbl504360223)

Gabapentin 300 mg capsule blister strip contains 90 capsules. The label indicates the manufacturer as Alkem Labs Ltd., Mumbai, India, with packaging by Unit Dose Services, LLC in Dania, Florida. The label includes storage instructions and a caution to keep out of reach of children. It shows the NDC number 50436-0223-3 and is marked RX only.*

FDA Label Image

Label Image (Lbl504360224)

Gabapentin 400 mg capsule unit dose label showing NDC 50436-0224-2. Contains 60 capsules. Manufactured by Alkem Labs Ltd., Mumbai, India. Label includes dosage strength, manufacturer location, lot number placeholder, expiration date placeholder, and storage instructions. Distributed by Unit Dose Services in Dania, Florida. RX only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.